These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

2000 related articles for article (PubMed ID: 33941925)

  • 1. Global virus tracker.
    Powell K
    Nature; 2021 May; 593(7857):160. PubMed ID: 33941925
    [No Abstract]   [Full Text] [Related]  

  • 2. Antibodies, epicenter of SARS-CoV-2 immunology.
    Pecetta S; Pizza M; Sala C; Andreano E; Pileri P; Troisi M; Pantano E; Manganaro N; Rappuoli R
    Cell Death Differ; 2021 Feb; 28(2):821-824. PubMed ID: 33500559
    [No Abstract]   [Full Text] [Related]  

  • 3. SARS-CoV-2 variants and convalescent plasma: reality, fallacies, and opportunities.
    Casadevall A; Henderson JP; Joyner MJ; Pirofski LA
    J Clin Invest; 2021 Apr; 131(7):. PubMed ID: 33621214
    [No Abstract]   [Full Text] [Related]  

  • 4. Fast-spreading COVID variant can elude immune responses.
    Callaway E
    Nature; 2021 Jan; 589(7843):500-501. PubMed ID: 33479534
    [No Abstract]   [Full Text] [Related]  

  • 5. Thinking more about therapy with convalescent plasma for COVID-19 patients.
    Han G; Zhou YH
    Hum Vaccin Immunother; 2020 Nov; 16(11):2601-2603. PubMed ID: 32643512
    [No Abstract]   [Full Text] [Related]  

  • 6. Change in Antibodies to SARS-CoV-2 Over 60 Days Among Health Care Personnel in Nashville, Tennessee.
    Patel MM; Thornburg NJ; Stubblefield WB; Talbot HK; Coughlin MM; Feldstein LR; Self WH
    JAMA; 2020 Nov; 324(17):1781-1782. PubMed ID: 32940635
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clearance of the SARS-CoV-2 Virus in an Immunocompromised Patient Mediated by Convalescent Plasma without B-Cell Recovery.
    Basheer M; Saad E; Laskar O; Schuster O; Rechnitzer H; Zisman-Rozen S; Azoulay D; Assy N
    Int J Mol Sci; 2021 Aug; 22(16):. PubMed ID: 34445605
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Neutralization of the SARS-CoV-2 Mu Variant by Convalescent and Vaccine Serum.
    Uriu K; Kimura I; Shirakawa K; Takaori-Kondo A; Nakada TA; Kaneda A; Nakagawa S; Sato K;
    N Engl J Med; 2021 Dec; 385(25):2397-2399. PubMed ID: 34731554
    [No Abstract]   [Full Text] [Related]  

  • 9. SARS-CoV-2 Neutralizing Human Antibodies Protect Against Lower Respiratory Tract Disease in a Hamster Model.
    Haagmans BL; Noack D; Okba NMA; Li W; Wang C; Bestebroer T; de Vries R; Herfst S; de Meulder D; Verveer E; van Run P; Lamers MM; Rijnders B; Rokx C; van Kuppeveld F; Grosveld F; Drabek D; Geurts van Kessel C; Koopmans M; Bosch BJ; Kuiken T; Rockx B
    J Infect Dis; 2021 Jun; 223(12):2020-2028. PubMed ID: 34043806
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Understanding neutralising antibodies against SARS-CoV-2 and their implications in clinical practice.
    Pang NY; Pang AS; Chow VT; Wang DY
    Mil Med Res; 2021 Aug; 8(1):47. PubMed ID: 34465396
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Therapeutic antibodies and fusion inhibitors targeting the spike protein of SARS-CoV-2.
    Jiang S; Zhang X; Du L
    Expert Opin Ther Targets; 2021 Jun; 25(6):415-421. PubMed ID: 32941780
    [No Abstract]   [Full Text] [Related]  

  • 12. Case Report: Effects of Anti-SARS-CoV-2 Convalescent Antibodies Obtained With Double Filtration Plasmapheresis.
    Curtò D; Tomatis F; Gastoldi S; Galbusera M; Noris M; Raimondi F; Lorini FL; Falanga A; Marchetti M; Remuzzi G; Ruggenenti P
    Front Immunol; 2021; 12():711915. PubMed ID: 34276706
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Structural Basis of a Human Neutralizing Antibody Specific to the SARS-CoV-2 Spike Protein Receptor-Binding Domain.
    Yang M; Li J; Huang Z; Li H; Wang Y; Wang X; Kang S; Huang X; Wu C; Liu T; Jia Z; Liang J; Yuan X; He S; Chen X; Zhou Z; Chen Q; Liu S; Li J; Zheng H; Liu X; Li K; Yao X; Lang B; Liu L; Liao HX; Chen S
    Microbiol Spectr; 2021 Oct; 9(2):e0135221. PubMed ID: 34643438
    [TBL] [Abstract][Full Text] [Related]  

  • 14. SARS-CoV-2 antibodies: Comparison of three high-throughput immunoassays versus the neutralization test.
    Laterza R; Schirinzi A; Bruno R; Genco R; Contino R; Ostuni A; Di Serio F
    Eur J Clin Invest; 2021 Jul; 51(7):e13573. PubMed ID: 33870493
    [No Abstract]   [Full Text] [Related]  

  • 15. A review of COVID-19 convalescent plasma use in COVID-19 with focus on proof of efficacy.
    Devarasetti PK; Rajasekhar L; Baisya R; Sreejitha KS; Vardhan YK
    Immunol Res; 2021 Feb; 69(1):18-25. PubMed ID: 33492637
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Convalescent Plasma Therapy for COVID-19: Lessons from SARS-CoV, MERS-CoV, and H1N1 Infection.
    Hosseini P; Rahimi H; Najafabadi MM; Ghorbani A; Najafabadi SK; Faridzadeh A; Arabpour J; Khormali E; Deravi N
    Acta Med Indones; 2021 Jan; 53(1):86-95. PubMed ID: 33818411
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Kinetics of Nucleocapsid, Spike and Neutralizing Antibodies, and Viral Load in Patients with Severe COVID-19 Treated with Convalescent Plasma.
    Thomopoulos TP; Rosati M; Terpos E; Stellas D; Hu X; Karaliota S; Bouchla A; Katagas I; Antoniadou A; Mentis A; Papageorgiou SG; Politou M; Bear J; Donohue D; Kotanidou A; Kalomenidis I; Korompoki E; Burns R; Pagoni M; Grouzi E; Labropoulou S; Stamoulis K; Bamias A; Tsiodras S; Dimopoulos MA; Pavlakis GN; Pappa V; Felber BK
    Viruses; 2021 Sep; 13(9):. PubMed ID: 34578426
    [TBL] [Abstract][Full Text] [Related]  

  • 18. High neutralizing potency of swine glyco-humanized polyclonal antibodies against SARS-CoV-2.
    Vanhove B; Duvaux O; Rousse J; Royer PJ; Evanno G; Ciron C; Lheriteau E; Vacher L; Gervois N; Oger R; Jacques Y; Conchon S; Salama A; Duchi R; Lagutina I; Perota A; Delahaut P; Ledure M; Paulus M; So RT; Mok CK; Bruzzone R; Bouillet M; Brouard S; Cozzi E; Galli C; Blanchard D; Bach JM; Soulillou JP
    Eur J Immunol; 2021 Jun; 51(6):1412-1422. PubMed ID: 33576494
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antibody response and therapy in COVID-19 patients: what can be learned for vaccine development?
    Lu L; Zhang H; Zhan M; Jiang J; Yin H; Dauphars DJ; Li SY; Li Y; He YW
    Sci China Life Sci; 2020 Dec; 63(12):1833-1849. PubMed ID: 33355886
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antibody resistance of SARS-CoV-2 variants B.1.351 and B.1.1.7.
    Wang P; Nair MS; Liu L; Iketani S; Luo Y; Guo Y; Wang M; Yu J; Zhang B; Kwong PD; Graham BS; Mascola JR; Chang JY; Yin MT; Sobieszczyk M; Kyratsous CA; Shapiro L; Sheng Z; Huang Y; Ho DD
    Nature; 2021 May; 593(7857):130-135. PubMed ID: 33684923
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 100.